載入...
Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells
BACKGROUND: PD-1/PD-L1 blockade can confer durable benefits in the treatment of metastatic cancers, but the response rate remains modest and potential adverse effects occur sometimes. Concentrating immunotherapeutic agents at the site of disease was believed to break local immune tolerance and reduc...
Na minha lista:
| 發表在: | J Hematol Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6482514/ https://ncbi.nlm.nih.gov/pubmed/31023384 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-019-0723-8 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|